Astrazeneca Dividends - AZN

Astrazeneca Dividends - AZN

Trade Now

Capital at risk Advertisement
Stock Name Stock Symbol Market Stock Type
Astrazeneca Plc AZN London Ordinary Share
  Price Change Price Change % Stock Price Last Trade
0.00 0.0% 9,944.00 01:00:00
Open Price Low Price High Price Close Price Previous Close
9,944.00
more quote information »
Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Astrazeneca AZN Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount
29/07/2022InterimUSX9331/12/202131/12/202211/08/202212/08/202212/09/20220
10/02/2022InterimUSX19731/12/202031/12/202124/02/202225/02/202228/03/2022287
29/07/2021InterimUSX9031/12/202031/12/202112/08/202113/08/202113/09/20210
16/02/2021InterimUSX19031/12/201931/12/202025/02/202126/02/202129/03/2021280
30/07/2020InterimUSX9031/12/201931/12/202013/08/202014/08/202014/09/20200
14/02/2020InterimUSX19031/12/201831/12/201927/02/202028/02/202030/03/2020280
25/07/2019InterimUSX9031/12/201831/12/201908/08/201909/08/201909/09/20190
14/02/2019FinalUSX19031/12/201731/12/201828/02/201901/03/201927/03/2019280
26/07/2018InterimUSX9031/12/201731/12/201809/08/201810/08/201810/09/20180
02/02/2018FinalUSX19031/12/201631/12/201715/02/201816/02/201819/03/2018280
27/07/2017InterimUSX9031/12/201631/12/201710/08/201711/08/201711/09/20170
02/02/2017FinalUSX19031/12/201531/12/201616/02/201717/02/201720/03/2017280
28/07/2016InterimUSX9031/12/201531/12/201611/08/201612/08/201612/09/20160
04/02/2016FinalUSX19031/12/201431/12/201518/02/201619/02/201621/03/2016280
30/07/2015InterimUSX9031/12/201431/12/201513/08/201514/08/201514/09/20150
05/02/2015FinalUSX19031/12/201331/12/201419/02/201520/02/201523/03/2015280
31/07/2014InterimUSX9031/12/201331/12/201413/08/201415/08/201415/09/20140
06/02/2014FinalUSX19031/12/201231/12/201319/02/201421/02/201424/03/2014280
01/08/2013InterimUSX9031/12/201231/12/201314/08/201316/08/201316/09/20130
31/01/2013FinalUSX19031/12/201131/12/201213/02/201315/02/201318/03/2013280
26/07/2012InterimUSX9031/12/201131/12/201208/08/201210/08/201210/09/20120
02/02/2012FinalUSX19531/12/201031/12/201115/02/201217/02/201219/03/2012280
28/07/2011InterimUSX8531/12/201031/12/201103/08/201105/08/201112/09/20110
27/01/2011FinalUSX18531/12/200931/12/201002/02/201104/02/201114/03/2011255
29/07/2010InterimUSX7031/12/200931/12/201002/08/201004/08/201013/09/20100
28/01/2010FinalUSX17131/12/200831/12/200903/02/201005/02/201015/03/2010230
30/07/2009InterimUSX5930/12/200830/06/200905/08/200907/08/200914/09/20090
29/01/2009FinalUSX15031/12/200731/12/200804/02/200906/02/200916/03/2009205
31/07/2008InterimUSX5530/12/200730/06/200808/08/200806/08/200815/09/20080
31/01/2008FinalUSX13531/12/200631/12/200706/02/200808/02/200817/03/2008187
26/07/2007InterimUSX5230/06/200630/06/200708/08/200710/08/200717/09/20070
01/02/2007FinalUSX12331/12/200531/12/200607/02/200709/02/200719/03/2007172
27/07/2006InterimUSX4930/12/200530/06/200609/08/200611/08/200618/09/20060
01/02/2006FinalUSX9231/12/200431/12/200508/02/200610/02/200620/03/2006130
29/07/2005InterimUSX3830/12/200430/06/200510/08/200512/08/200519/09/20050
27/01/2005FinalUSX64.531/12/200331/12/200409/02/200511/02/200521/03/200594
22/07/2004InterimUSX29.530/12/200330/06/200411/08/200413/08/200420/09/20040
29/01/2004FinalUSX5431/12/200231/12/200318/02/200420/02/200406/04/200479.5
24/07/2003InterimUSX25.530/12/200230/06/200320/08/200322/08/200306/10/20030
30/01/2003FinalUSX4731/12/200131/12/200219/02/200321/02/200307/04/200370
25/07/2002InterimUSX2330/12/200130/06/200221/08/200223/08/200207/10/20020
31/01/2002FinalUSX4731/12/200031/12/200120/02/200222/02/200208/04/200270
26/07/2001InterimUSX2330/12/200030/06/200122/08/200124/08/200105/10/20010
08/02/2001FinalUSX4731/12/199931/12/200021/02/200123/02/200109/04/200170
01/08/2000InterimUSX2330/12/199930/06/200004/09/200008/09/200023/10/20000
24/02/2000FinalUSX4731/12/199831/12/199906/03/200010/03/200017/04/200070
03/08/1999InterimUSX2330/12/199830/06/199906/09/199910/09/199925/10/19990

Top Dividend Posts

Top Posts
Posted at 04/10/2022 07:10 by lostabillion
AZN eyeing up Avacta!?!
Posted at 02/10/2022 11:03 by bostonborn
Today's Questor in the telegraph has AZN as a buy. Can someone please post the complete article. It was tipped in the Times on Thursday or Friday. It may be a 'repeat' of this article. Summary of which was 'great pipeline of new drugs coming through over the next year or two, which should bring growth; also a 'safe' share'
Posted at 26/9/2022 21:46 by sb34
AZN Plc share going to match £115 price anytime soon over the next few weeks ??
Posted at 12/9/2022 07:57 by gateside
Dividend paid into my account this morning. Interactive Investor are always very prompt with their dividend payments.
Posted at 29/7/2022 14:38 by philanderer
ShoreCap stays at 'buy' on AstraZeneca, sees further upgrades ahead on product pipeline Analysts at ShoreCap reiterated their 'buy' recommendation for shares of drugs giant AstraZeneca, describing its second quarter top-line growth of 37% year-on-year at constant exchange rates "impressive". "AZN have delivered a strong second quarter, with Q2 benefitting from a full quarter of Alexion integration and several products beating consensus expectations," analyst Dr.Susie Jana said in a research note sent to clients. "Oncology was in line overall due to strong commercial execution and lower COVID-19 related headwinds than anticipated." The analyst also called attention to the fact that AstraZeneca was reinvesting its strong revenues into research and development. And there was more yet to come. "AZN has a strong mid to late-stage pipeline, we expect product and candidate related news flow in 2023 to lead to further upgrades. A strong set of results underpinning the long-term growth story," she added. "AZN shares trade on a FY23F PER of 16.8x, a c 5% premium versus US and European peers (mean 16.1x), which we believe is warranted based on its industry-leading earnings growth and pipeline prospects." Sharecast.com
Posted at 29/7/2022 08:15 by gibbs1
AstraZeneca PLC on Friday reported a swing to second-quarter net loss after booking a large foreign-exchange charge in its accounts, but raised its full-year revenue guidance due to better-than-expected Covid-19 medicine revenue. The Anglo-Swedish pharma giant said it now expects to report a low twenties percentage rise in total revenue for the year, up from previous guidance of high teens percentage. It also said revenue from Covid-19 medicines are expected to be flat compared with 2021. It had previously guided for a low-to-mid twenties percentage fall. AstraZeneca posted a net loss of $372 million for the quarter compared with a profit of $1.19 billion for the same period a year earlier. Revenue for the quarter rose to $10.77 billion, from $8.22 billion. Revenue consensus was $10.45 billion. Core earnings per share--one of the company's preferred metrics--rose to $1.72 in the quarter, compared with $0.90 and a consensus of $1.57. Consensus figures have been taken from FactSet and are based on 16 analysts' projections. AstraZeneca reiterated that it expects core EPS growth in the mid-to-high twenties percentage. The board has increased its interim dividend to $0.93 a share compared with $0.90 for the first half of 2021. Write to Ian Walker at ian.walker@wsj.com (END) Dow Jones Newswires July 29, 2022 02:54 ET (06:54 GMT)
Posted at 15/7/2022 11:35 by dudishes
Waldron, yes sold GSK, got the gitters. AZN, two reasons, the buy in France and I think it's peaked for now. I'll be back (maybe catch the divi)!
Posted at 08/7/2022 17:23 by waldron
thought you were keeping AZN Dud and sold GSK
Posted at 06/7/2022 15:31 by diku
AZN paper is so rich...
Posted at 14/2/2022 10:34 by beckers2008
HL View/Comment published on the 10th Feb: AstraZeneca's coronavirus vaccine has made it a household name worldwide, but the group's promise to sell the vaccine at cost ''during the pandemic'' means it's padded revenue but not profits. 2022 will pave a new road for the group's coronavirus medicines business--with vaccine sales waning and a monoclonal antibody treatment making up a larger proportion of sales, we can expect to see some of those dollars start to funnel through to the bottom line. This in addition to the potential growth runway coming from the Alexion acquisition have given management the confidence to increase shareholder returns, but remember dividends are variable and not guaranteed. Alexion brings rare disease treatments into the AZN fold, a fundamentally attractive area of the pharmaceutical market. The combination of Astra's massive distribution network and Alexion's specialized drugs should bring about a powerful windfall in the coming years. Rare diseases are, by definition, uncommon. In the past spending millions, perhaps billions, on researching a drug to treat a few tens of thousands of patients worldwide didn't make financial sense. Instead attention focused on treatments for common diseases, like asthma, with patients stretching into the tens of millions. As a result, only around 5% of designated rare diseases have approved treatments. More recently that attitude has shifted. While major diseases may have large markets, they also attract lots of competition. That means individual drugs companies can end up with a relatively small slice of a large pie. Competition in rare diseases is far lower - a drug company which develops a treatment for a previously unaddressed illness will likely end up serving the entire market and can probably attach a hefty price tag to boot. It's also unlikely a competitor will develop a more effective alternative, since competition is so much lower. Increased interest in the sector means the global rare disease market is forecasted to grow by a low double-digit percentage. Breaking into this market didn't come cheap, though. The acquisition more than doubled Astra's debt pile and sent free cash into the red. But this pales in comparison to the potential growth the combination offers. This is particularly true when it comes to emerging markets. Alexion's been primarily selling to the US and Europe, but under Astra's wing a greater proportion can be sold further afield. This is of course dependent on regulatory approval, but as AZN already has footholds in these markets it should make the process more efficient. Cash flow will be of utmost importance moving forward--debt now stands at more than 3 times underlying cash profits. With interest rates on the rise, we'd like to see that come down to more manageable levels. Shareholder returns are also marching higher, so the demands on cash are not insignificant. Any missteps in the Alexion integration, and the group will either have to saddle itself with more debt or trim the dividend. Overall we think Astra is pretty well placed. It's too early to say whether the Alexion deal will deliver on its potential, but a strong core business and the promise of rising coronavirus treatment profits are encouraging. If all goes to plan the future is bright.
ADVFN Advertorial
Your Recent History
LSE
AZN
Astrazenec..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20221006 07:05:38